# KLOW Peptide Benefits in the Research Literature | KLOW Order

> KLOW peptide benefits in the research literature span tissue repair, collagen synthesis, gut inflammation, and skin biology. A cited summary of what each component's preclinical record shows.

## BPC-157 and TB-500: Tissue Repair Research

The tissue-repair research on KLOW peptide's two recovery components is the foundation of the blend.

BPC-157 at 10 μg/kg/day (intraperitoneal) in rats accelerated Achilles tendon healing after surgical transection: improved Achilles Functional Index scores, better biomechanical properties (load capacity, stiffness, elasticity), increased fibroblast counts, improved collagen organization, and reduced inflammation — all measured against controls [4]. In a 90-day rat MCL healing study, the same dose via intraperitoneal, topical cream, and oral drinking-water routes all showed consistent functional, biomechanical, macroscopic, and histological improvements, establishing multiple research-feasible administration routes [23].

BPC-157 also dose- and time-dependently increases growth hormone receptor (GHR) expression in tendon fibroblasts — at both mRNA and protein levels — and subsequent growth hormone addition increases fibroblast proliferation via the JAK2 signaling pathway [3]. The upstream VEGFR2 mechanism has been confirmed in human vascular endothelial cells in vitro and in a rat hindlimb ischemia model in vivo [1].

TB-500 (thymosin beta-4) at topical and intraperitoneal doses produced 42% faster reepithelialization at day 4 and 61% faster at day 7 versus saline controls in rat wound models [8]. Across dermal, corneal, and cardiac wound models, thymosin beta-4 reduced myofibroblast numbers and promoted new blood vessel formation [7]. A 2025 study using engineered tandem thymosin beta-4 demonstrated superior corneal wound healing and reduced scarring versus native TB-4 [28].

The BPC-157/TB-500 pairing works from complementary angles: BPC-157 drives angiogenesis from the endothelial growth factor axis; TB-500 drives cell migration from the actin cytoskeletal axis. These mechanisms are additive in principle. No published study examines co-administration [25].

## KLOW Peptide Onset: What Preclinical Research Suggests

BPC-157 tendon and bone studies show measurable healing improvements at 1-2 weeks in rodent injury models [23]. The short IV elimination half-life (approximately 15.2 minutes in rats) means tissue exposure depends on dosing frequency and route [6].

TB-500 wound-closure acceleration is measurable at day 4 (42% improvement) and increases by day 7 (61% improvement) [8].

GHK-Cu collagen synthesis upregulation is measured in fibroblast cultures at 72 hours [11]. In rodent wound models, wound closure acceleration is seen at 5-7 days. GHK-Cu-liposomes shortened scald wound healing to 14 days post-injury in mice [13]. Small human topical studies have reported skin texture improvements at 4-8 weeks [11].

KPV shows rapid onset in NF-kB blocking assays — measurable IL-8 suppression at concentrations ≥ 1 μg/mL [15]. In murine colitis models, measurable protective effects are seen within the study windows [14][16].

No published timeline exists for the full KLOW combination.

## GHK-Cu and Skin Research in the KLOW Blend

GHK-Cu is the mass-dominant KLOW component at 50 mg. GHK is a naturally occurring tripeptide found in human plasma that declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [26]. When complexed with copper(II) to form GHK-Cu, it stimulates collagen and glycosaminoglycan synthesis at 1-10 nM concentrations in fibroblasts, accelerates wound healing in animal models, and improves skin density and firmness in human topical placebo-controlled studies [11].

Collagen synthesis stimulation in human fibroblast cultures begins at 10^-12 M and maximizes at 10^-9 M — independent of cell proliferation changes [10].

A 2024 review confirmed collagen synthesis enhancement while identifying skin permeability as the key limitation for topical delivery [22]. 31.2% of human genes show expression changes of 50% or greater when exposed to GHK; 59% of affected genes are upregulated [12].

## KLOW and Skin Inflammation Research

Most cutaneous cell types express MC1R, which mediates modulation of inflammation, cytoprotection, antioxidative defense, and collagen turnover [18]. KPV, as a truncated alpha-MSH fragment, retains anti-inflammatory effects without the pigmentation-inducing activity of the full hormone [18].

GHK-Cu contributes to skin inflammation research through SIRT1/STAT3 pathway modulation, extending its research profile from skin to gut-inflammation contexts [27].

No published clinical study examines KLOW or any of its four components in combination for rosacea or other specific skin inflammatory diagnoses.

## Gut and Mucosal Inflammation Research in the KLOW Blend

KLOW peptide brings two components with gut inflammation preclinical records: BPC-157 and KPV.

BPC-157 has been administered in rodent IBD models via oral drinking water and intraperitoneal injection, demonstrating anti-ulcer, mucosal healing, and cytoprotective activity [5]. The compound entered clinical trials for IBD under designations PL-10, PLD-116, and PL 14736 (Pliva, Croatia) [5].

KPV reduces colitis disease severity in both DSS- and TNBS-induced murine colitis models at nanomolar oral concentrations via PepT1-mediated transport [16]. In a murine AOM/DSS colitis-associated cancer model, KPV prevented tumor development in wild-type mice but not in PepT1-knockout mice [17].

A 2025 study demonstrated GHK-Cu alleviates DSS-induced ulcerative colitis in mice via SIRT1/STAT3 pathway, suppressing TNF-alpha, IL-6, and IL-1beta, and restoring tight junction proteins ZO-1 and Occludin [27].

Three gut-active mechanisms in one vial. No published study examines BPC-157, KPV, and GHK-Cu together in a gut inflammation model.

## GHK-Cu Scar and Wound Healing Research

GHK-Cu-liposomes accelerated scald wound healing in mice: 33.1% increased HUVEC proliferation rate, upregulated VEGF and FGF-2, and wound healing time shortened to 14 days versus controls [13].

For topical scar applications, the key limitation is skin permeability — GHK and GHK-Cu are hydrophilic molecules [22]. A small number of human topical studies suggest improved scar appearance and skin texture [11].

## References

[1] Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Chang CH et al. BPC 157 enhances GHR expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://pubmed.ncbi.nlm.nih.gov/25415472/
[4] Krivic A et al. BPC 157: Promoted tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/
[5] Sikiric P et al. BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. https://pubmed.ncbi.nlm.nih.gov/21548867/
[6] He L et al. Pharmacokinetics of BPC-157 in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
[7] Philp D, Kleinman HK. Animal studies with thymosin beta. Ann N Y Acad Sci. 2010;1194:81-86. https://pubmed.ncbi.nlm.nih.gov/20536453/
[8] Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[10] Maquart FX et al. Stimulation of collagen synthesis by GHK-Cu2+. FEBS Lett. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/
[11] Pickart L et al. GHK Peptide in Skin Regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[12] Pickart L, Margolina A. Regenerative Actions of GHK-Cu. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[13] Wang X et al. GHK-Cu-liposomes accelerate scald wound healing. Wound Repair Regen. 2017;25(2):270-278. https://pubmed.ncbi.nlm.nih.gov/28370978/
[14] Kannengiesser K et al. KPV anti-inflammatory potential in murine IBD models. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/
[15] Land SC. Mechanism of KPV action. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. https://pmc.ncbi.nlm.nih.gov/articles/PMC3403564/
[16] Dalmasso G et al. PepT1-mediated KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[17] Viennois E et al. Critical role of PepT1 in colitis-associated cancer. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. https://pubmed.ncbi.nlm.nih.gov/27458604/
[18] Bohm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing? Exp Dermatol. 2019;28(3):219-224. https://pubmed.ncbi.nlm.nih.gov/30661264/
[21] Pickart L et al. Effect of GHK on Gene Expression Relevant to Nervous System Function. Brain Sci. 2017;7(2):20. https://pubmed.ncbi.nlm.nih.gov/28212278/
[22] Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide. Bioimpacts. 2024;15:30071. https://pubmed.ncbi.nlm.nih.gov/39963574/
[23] Cerovecki T et al. BPC 157 improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. https://pubmed.ncbi.nlm.nih.gov/20225319/
[25] Pickart L et al. GHK Peptide. [KLOW compositional reference] Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[26] Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and aging. Oxid Med Cell Longev. 2012;2012:324832. https://pubmed.ncbi.nlm.nih.gov/22666519/
[27] Mao S et al. Beneficial effects of GHK-Cu on an experimental model of colitis. Front Pharmacol. 2025;[vol]:1551843. https://pubmed.ncbi.nlm.nih.gov/40672369/
[28] Nguyen J et al. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Invest Ophthalmol Vis Sci. 2025;66(14):31. https://pubmed.ncbi.nlm.nih.gov/41235866/

---

Four spot-ink literatures, one dark-stock page — editorial summaries of what the peer-reviewed studies actually printed, held by no clinic and sold by no one.